Immune Thrombocytopenia (ITP) in a Patient with Relapsing-Remitting Multiple Sclerosis (RRMS) Associated with b-Interferon-1α Treatment

Indian Journal of Pharmaceutical Education and Research

  • Vahid Shaygannejad1Isfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Isfahan, IRAN.,
  • Emad Fayyazi2Department of Neurology, Isfahan University of Medical Sciences, Isfahan, IRAN.
  • Omid Mirmosayyeb3Medical students’ research Committee, Isfahan University of Medical Sciences, Isfahan, IRAN.
  • Nafiseh Toghianifar4Non-communicable Disease Unit, Vice Chancellor for Clinical Affairs, Isfahan University of Medical Sciences, Isfahan, IRAN.

Volume 52 Issue 3 Pages 540-542

DOI: 10.5530/ijper.52.3.62

Abstract

Immune thrombocytopenia is an isolated thrombocytopenia not related to other etiologies of thrombocytopenia.1 The diagnosis relies mainly on exclusion of other conditions.2,3 The incidence of ITP among adults has been estimated to be 3.3 per 100,000 persons in Europe according to a review study in 2009.4 ITP may be induced by drugs.2 In this type of ITP, a drug induces production of antibodies against platelets and causes destruction and reduction of platelets.2 This is usually transient and improves after withdrawal of the offending drug.1,2

Keywords

  • Cinnovex
  • Immune thrombocytopenia
  • neurologic
IJOPP

Loading…